kabutan

Astellas Pharma, Net Income Forecast for the Fiscal Year Revised Upward by 39%, Highest in Seven Terms

Wed Feb 4, 2026 3:30 pm JST Earnings

4503 Astellas Pharma Inc. 【IFRS】

Earnings Report

Astellas Pharma Inc. <4503> [TSE Prime] announced its financial results (based on IFRS) after the market closed on February 4th (15:30). The consolidated net income/loss for the cumulative third quarter of the fiscal year ending March 2026 (April to December) turned into a profit of 248 billion yen (compared to a loss of 24.1 billion yen in the same period last year).

In addition, the full-year forecast for consolidated net income has been revised upward 38.9%, from the previous forecast of 180 billion yen to 250 billion yen (compared to 50.7 billion yen in the previous period), increasing the growth rate from 3.5 times to 4.9 times, reaches new record high for the first time in seven terms.

Based on the full-year plan announced by the company after the upward revision, our estimate of the consolidated net income for the October to March period (second half) is expected to increase 3.2 times, from the previous forecast of 32.3 billion yen to 102 billion yen (compared to a loss of 22.7 billion yen in the same period of the previous year).

In the most recent three-month period, from October to December (3Q), the consolidated net income/loss turned to a profit of 100 billion yen (compared to a loss of 97.6 billion yen in the same period last year). The operating profit/loss margin drastically improved from -22.5% in the same period last year to 23.5%.

Kabutan News

Actual Results

Accumulated Results 3rd Quarter
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Progress Rate vs. First Half Announce Accounting Standards
Apr - Dec, 2023 1,189,070 74,119 73,630 50,323 28.1 294.9 Feb 5, 2024 IFRS
Apr - Dec, 2024 1,453,029 -22,481 -29,317 -24,149 -13.5 ー Feb 4, 2025 IFRS
Apr - Dec, 2025 1,601,320 333,880 328,563 248,014 138.5 99.6 Feb 4, 2026 IFRS
YoY +10.2% － － － －

Guidance Update

Second Half Update

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Oct - Mar, 2025 Prev 999,886 40,622 35,394 32,365 18.1 39 Oct 30, 2025 IFRS
Oct - Mar, 2025 New 1,069,886 140,622 135,394 102,365 57.1 39 Feb 4, 2026 IFRS
Revision Rate +7.0% +246.2% +282.5% +216.3% +216.2%

Full Year Update

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2026 Prev 2,030,000 240,000 230,000 180,000 100.5 78 Oct 30, 2025 IFRS
Mar, 2026 New 2,100,000 340,000 330,000 250,000 139.6 78 Feb 4, 2026 IFRS
Revision Rate +3.4% +41.7% +43.5% +38.9% +38.9%

Current Period Guidance

Second Half Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Oct - Mar, 2024 976,702 -52,671 -57,805 -22,764 -12.7 37 Apr 25, 2025 IFRS
Oct - Mar, 2025 Guidance 1,069,886 140,622 135,394 102,365 57.1 39 Feb 4, 2026 IFRS
YoY +9.5% － － － －

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2024 1,603,672 25,518 24,969 17,045 9.5 70 Apr 25, 2024 IFRS
Mar, 2025 1,912,323 41,039 31,237 50,747 28.4 74 Apr 25, 2025 IFRS
Mar, 2026 Guidance 2,100,000 340,000 330,000 250,000 139.6 78 Feb 4, 2026 IFRS
YoY +9.8% +728.5% +956.4% +392.6% +392.2%

Quarterly Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Operating Profit Margin Announce Accounting Standards
Oct - Dec, 2024 517,408 -116,191 -118,359 -97,660 -54.6 -22.5 Feb 4, 2025 IFRS
Jan - Mar, 2025 459,294 63,520 60,554 74,896 41.8 13.8 Apr 25, 2025 IFRS
Apr - Jun, 2025 505,794 94,647 90,416 68,422 38.2 18.7 Jul 30, 2025 IFRS
Jul - Sep, 2025 524,320 104,731 104,190 79,213 44.2 20.0 Oct 30, 2025 IFRS
Oct - Dec, 2025 571,206 134,502 133,957 100,379 56.1 23.5 Feb 4, 2026 IFRS
YoY +10.4% － － － －

Related Articles